Company news
Prothena Corporation plc news in 2020
Prothena Corporation plc's news releases, calls and decks from 2020, newest first.
Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis
December 8, 2020
Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update
November 3, 2020
Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020
November 3, 2020
Prothena to Report Third Quarter 2020 Financial Results on November 4
October 27, 2020
Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders
September 2, 2020
Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update
August 5, 2020
Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders
August 4, 2020
Prothena to Report Second Quarter 2020 Financial Results on August 6
July 29, 2020
Prothena Reports First Quarter 2020 Financial Results and Provides R&D Update and Updated Financial Guidance
May 5, 2020
Prothena to Report First Quarter 2020 Financial Results on May 6
April 28, 2020
Prothena Provides Additional Information Regarding Upcoming Annual General Meeting of Shareholders in Response to COVID-19
April 23, 2020
Update on Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease
April 21, 2020
Prothena Announces Appointment of Brandon Smith as Chief Business Officer
March 2, 2020
Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update
February 11, 2020
Prothena to Report Fourth Quarter and Full Year 2019 Financial Results and Host Webcast Conference Call on February 12
February 4, 2020